United Kingdom
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from RxCelerate.
Cambridge, UK, 18 September 2024: PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and RxCelerate, a leading international out-sourced drug discovery and development service provider, today announced the successful completion of a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies.
Identification of suitable candidates from an initial virtual drug screen against a novel target in CAD, discovered by PlaqueTec, formed the basis for the collaboration with RxCelerate. The collaborative project was aimed at assessing the small molecules in a functional cell-based assay offered through RxCelerate’s bespoke services. The project has enabled the lead compounds to be characterised successfully, demonstrating the value of the assay in the progress of PlaqueTec’s mission to endotype CAD and develop personalised interventions to transform patient care. If the target is validated in PlaqueTec’s ongoing BIOPATTERN trial, the collaborators plan to bring forward other lead compounds for further investigation, alongside further drug screening for other new targets identified and validated in BIOPATTERN.
This is the News section of the company profile page for RxCelerate on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
